Roche (RHHBY) News Today

Roche Holding AG (OTCMKTS: RHHBY) shares have weakened as technical momentum deteriorated, but the company received a potentially meaningful regulatory catalyst for its neuroscience portfolio.

• Positive Sentiment: The U.S. FDA granted Priority Review to Roche’s supplemental application for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmune disorder with no approved treatments. The application is supported by data showing a 68% reduction in relapses, and an FDA decision is expected by January 10, 2027. Priority review could accelerate a new indication and expand Enspryng’s commercial opportunity, although it does not guarantee approval. Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
• Neutral Sentiment: Amgen and AstraZeneca reported that their Imdelltra-Imfinzi combination produced a survival benefit in first-line extensive-stage small-cell lung cancer. The result may broaden the drugs’ reach and reinforce competitive pressure in oncology, but the report does not directly change Roche’s products or forecasts. AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
• Negative Sentiment: RHHBY moved below its 50-day moving average, a technical warning that short-term selling pressure has increased and that momentum investors may remain cautious. The shares are still above the 200-day moving average, suggesting the longer-term trend has not clearly broken down. Roche Stock Passes Below 50 Day Moving Average